"""
Question: 1101

Evidence: A retrospective study was conducted with patients with AHI from 2012 to 2017 in West China Hospital. A total of 47 patients with AHI were found using a fourth‐generation kit.

Rationale: The paper explicitly states that it is a retrospective study conducted with patient data from 2012 to 2017, and presents findings from this specific cohort (47 patients with AHI). This indicates the data being reported is from the authors' own study and has not been published before.

Answer: Yes
"""

"""
Question: 1102

Evidence: We performed genotyping and drug resistance detection of AHI strains, among which 34 were sequenced successfully. In these AHI strains, four HIV clades were identified: CRF07_BC (64.71%), CRF01_AE (26.47%), CRF55_01B (5.88%), and CRF08_BC (2.94%).

Rationale: The paper describes a process of sequencing HIV strains from patients, identifying specific genetic forms (clades), and analyzing them for drug resistance. This constitutes reporting HIV sequences.

Answer: Yes
"""

"""
Question: 1103

Evidence: The paper content describes a clinical and molecular epidemiological study of patients with Acute HIV Infection. No mention is made of in vitro passage experiments, which involve growing viruses in cell culture over multiple cycles.

Rationale: After a thorough review of the entire paper content, no references to in vitro passage experiments are found. The methods involve patient sample collection, diagnostic testing, and direct sequencing from clinical specimens.

Answer: No
"""

"""
Question: 1104

Evidence: The drug resistance mutation rate was relatively high (17.65%) and five different mutations were identified. Mutation sites and genotypes of drug resistance were determined using the Stanford University HIV Drug Resistance Database.

Rationale: The paper reports genotypic drug resistance data (i.e., the presence of specific mutations known to confer resistance). It does not report in vitro susceptibility data, which would involve directly testing viral isolates against antiretroviral drugs in a laboratory setting to determine concentrations that inhibit viral growth (e.g., IC50).

Answer: No
"""

"""
Question: 2101

Evidence: The paper content describes sequencing and genotyping of HIV isolates from patients but does not list any GenBank accession numbers in the provided text, tables, or figures.

Rationale: A search through the entire provided paper content, including the results, methods, and tables, finds no mention of GenBank or specific accession numbers for the sequenced HIV isolates.

Answer: No
"""

"""
Question: 2102

Evidence: The paper content describes sequencing and genotyping of HIV isolates from patients but does not list any GenBank accession numbers in the provided text, tables, or figures.

Rationale: A search through the entire provided paper content, including the results, methods, and tables, finds no mention of GenBank or specific accession numbers for any HIV isolates, whether from the study or from laboratory strains.

Answer: No
"""

"""
Question: 2103

Evidence: The paper content describes sequencing and genotyping of HIV isolates from patients but does not list any GenBank accession numbers in the provided text, tables, or figures.

Rationale: A search through the entire provided paper content, including the results, methods, and tables, finds no mention of GenBank or specific accession numbers.

Answer: NA
"""

"""
Question: 2202

Evidence: Primary drug resistance mutations occurred in six cases, two in PR region and four in RT region. Mutations in PR region were M46I and Q58E. Four drug resistance mutations in RT region were all nonnucleoside reverse transcriptase inhibitors with one E138A, one V179D, and two V179Es.

Rationale: The paper provides a list of specific drug resistance mutations (M46I, Q58E, E138A, V179D, V179E) found in the study population. However, it reports the aggregate count of each mutation across all individuals rather than providing a list of all mutations for each individual sequenced isolate.

Answer: No
"""

"""
Question: 2301

Evidence: The screening procedure is shown in Figure 1 . The Elecsys HIV combi PT assay (the fourth-generation assay) was used for screening HIV infection. All data were recorded anonymously.

Rationale: The paper focuses on HIV screening and characterization. The assays used (e.g., "HIV combi PT") and the context of the study in China imply the study is on HIV-1, which is the predominant species globally and in China. No mention of HIV-2 is made.

Answer: HIV-1
"""

"""
Question: 2302

Evidence: In these AHI strains, four HIV clades were identified: CRF07_BC (64.71%), CRF01_AE (26.47%), CRF55_01B (5.88%), and CRF08_BC (2.94%).

Rationale: The paper explicitly lists the subtypes (also referred to as clades or genetic forms) of the successfully sequenced viruses from the 34 patients.

Answer: CRF07_BC, CRF01_AE, CRF55_01B, CRF08_BC
"""

"""
Question: 2303

Evidence: Complementary DNA was synthesized... and then used to amplify a product of 1.3 kb including the whole PR gene and the first 300 amino acids of RT gene located in pol sequence.

Rationale: The methods section clearly states which HIV genes were targeted for sequencing: the protease (PR) gene and a partial sequence of the reverse transcriptase (RT) gene. Both of these are parts of the HIV pol gene.

Answer: PR, RT (partial, part of the pol gene)
"""

"""
Question: 2304

Evidence: Complementary DNA was synthesized... and then used to amplify a product of 1.3 kb including the whole PR gene and the first 300 amino acids of RT gene located in pol sequence.

Rationale: The paper explicitly states that a region of the HIV pol gene, encompassing the entire PR (protease) and a portion of the RT (reverse transcriptase), was amplified and sequenced.

Answer: Yes
"""

"""
Question: 2401

Evidence: A retrospective study was conducted with patients with AHI from 2012 to 2017 in West China Hospital. Importantly, CRF55_01B was first reported in Chengdu, Sichuan province.

Rationale: The study was conducted at West China Hospital in Sichuan province, China. The sequences are from patients identified at this hospital, and the discussion specifically mentions findings relevant to Sichuan province.

Answer: Sichuan province, China
"""

"""
Question: 2402

Evidence: A retrospective study was conducted with patients with AHI from 2012 to 2017 in West China Hospital. The number of AHI from 2015 to 2017 was 26 (55.32% of all the AHI), slightly higher than that from 2012 to 2014 (21, which was 44.68% of all the AHI).

Rationale: The paper specifies the study period from which samples were obtained: 2012 to 2017. It further breaks down the number of cases between 2012-2014 and 2015-2017.

Answer: 2012 to 2017
"""

"""
Question: 2502

Evidence: PCRs were sent to TsingKe Biological Technology in Chengdu for direct DNA sequencing. ChromasPro 1.33 software was used to edit and stitch sequences.

Rationale: The method describes "direct DNA sequencing" of PCR products and the use of ChromasPro software for sequence editing, which are hallmarks of Sanger sequencing. No mention of Next-Generation Sequencing (NGS) technologies is made.

Answer: Yes
"""

"""
Question: 2503

Evidence: The paper content describes sequencing performed by "direct DNA sequencing" and uses software (ChromasPro) typical for analyzing Sanger sequencing data.

Rationale: There is no mention of terms associated with NGS (e.g., next-generation sequencing, deep sequencing, Illumina, Ion Torrent, etc.) in the methods or any other section of the paper.

Answer: No
"""

"""
Question: 2504

Evidence: Nested polymerase chain reaction (PCR)-based detection of the product... PCRs were sent to TsingKe Biological Technology in Chengdu for direct DNA sequencing.

Rationale: The paper describes using nested PCR followed by "direct DNA sequencing" of the PCR product. This method sequences a mixture of PCR amplicons directly without an intermediate cloning step to separate individual viral genomes.

Answer: No
"""

"""
Question: 2505

Evidence: The paper describes using nested PCR followed by "direct DNA sequencing" of the PCR product.

Rationale: Single genome sequencing (SGS) is a specific method that involves diluting templates to ensure amplification from a single molecule, which is not described. The method used is standard bulk PCR and direct sequencing.

Answer: No
"""

"""
Question: 2506

Evidence: The paper describes using nested PCR followed by "direct DNA sequencing" of the PCR product.

Rationale: The methods section describes PCR amplification and direct sequencing of the resulting product mixture. There is no mention of inserting the PCR product into a vector or a molecular cloning step.

Answer: No
"""

"""
Question: 2601

Evidence: HIV-1 RNA was extracted from blood using QIAamp Viral RNA Mini Kit. HIV-1 RNA results were collected from the hospital laboratory information system.

Rationale: The extraction of viral RNA from blood and the mention of HIV-1 RNA viral load results indicate that sequencing was performed on virus from plasma, which contains free viral particles.

Answer: Yes
"""

"""
Question: 2602

Evidence: The paper describes RNA extraction from blood and sequencing from that RNA. It does not mention cell separation, DNA extraction, or PBMC culture.

Rationale: The methods specify extracting "HIV-1 RNA" from blood, which targets the viral RNA in plasma. There is no description of procedures related to PBMCs (Peripheral Blood Mononuclear Cells) or proviral DNA.

Answer: No
"""

"""
Question: 2603

Evidence: We performed genotyping and drug resistance detection of AHI strains, among which 34 were sequenced successfully.

Rationale: The paper states that 34 AHI strains were successfully sequenced. Given that the sequencing was performed on viral RNA extracted from blood, these 34 sequences are from plasma virus.

Answer: 34
"""

"""
Question: 2604

Evidence: The paper describes sequencing from viral RNA extracted from blood, not from PBMC DNA.

Rationale: There is no mention of PBMC isolation, DNA extraction, or sequencing from PBMCs in the paper.

Answer: 0
"""

"""
Question: 2605

Evidence: AHI is a vital stage in the process of HIV infection. During this period of time, viral loads are at the peak of the whole course of HIV infection.

Rationale: The study focuses on Acute HIV Infection (AHI), a stage characterized by very high levels of viral replication and high plasma viral loads, as stated in the introduction.

Answer: Yes
"""

"""
Question: 2606

Evidence: The paper describes sequencing from viral RNA extracted from blood. HIV-1 RNA was extracted from blood using QIAamp Viral RNA Mini Kit.

Rationale: The methods explicitly state that viral RNA was extracted for sequencing. Sequencing from the proviral DNA reservoir would require extraction of DNA from PBMCs, which is not described.

Answer: No
"""

"""
Question: 2701

Evidence: Patients with AHI were almost all males (91.49%) with a median age of 26 years.

Rationale: The reported median age is 26 years, which classifies as adults. There is no mention of infants, children, or pediatric patients in the demographic data.

Answer: No
"""

"""
Question: 2702

Evidence: The paper describes a retrospective study of patients identified through routine hospital HIV screening. No mention is made of a clinical trial or intervention study.

Rationale: The study design is observational (retrospective analysis of routinely collected data). There is no description of patients being enrolled in a clinical trial.

Answer: No
"""

"""
Question: 2703

Evidence: The paper describes a retrospective study of patients identified through routine hospital HIV screening. No mention is made of a clinical trial.

Rationale: As the study is not based on a clinical trial, it follows that not all, and in fact none, of the individuals were in a clinical trial.

Answer: No
"""

"""
Question: 3101

Evidence: We performed genotyping and drug resistance detection of AHI strains, among which 34 were sequenced successfully.

Rationale: The paper states that genotyping was performed on AHI strains, and 34 were successfully sequenced. This implies that samples were obtained from at least 34 individuals for the purpose of HIV sequencing.

Answer: 34
"""

"""
Question: 3102

Evidence: A total of 47 patients with AHI were found... We performed genotyping and drug resistance detection of AHI strains, among which 34 were sequenced successfully.

Rationale: The study identified 47 patients with AHI, but sequencing was only successful for 34 of them. Therefore, not all individuals in the paper underwent HIV sequencing.

Answer: No
"""

"""
Question: 4101

Evidence: The study focuses on Acute HIV Infection (AHI). AHI refers to the period from viral acquisition to emergence of specific antibodies.

Rationale: By definition, patients with Acute HIV Infection are in the very early stage of infection, before the development of antibodies, and are extremely unlikely to have started Antiretroviral Therapy (ART). The paper does not mention any patients being on ART at the time of sampling.

Answer: Yes
"""

"""
Question: 4102

Evidence: The study focuses on Acute HIV Infection (AHI). AHI refers to the period from viral acquisition to emergence of specific antibodies.

Rationale: The paper defines AHI as the period from infection to seroconversion. Patients at this stage are, by definition, not yet diagnosed and are therefore almost certainly ART-naive. There is no mention of any patients having received ART prior to sample collection.

Answer: No
"""

"""
Question: 4103

Evidence: The study focuses on Acute HIV Infection (AHI). The paper does not mention any patients receiving ART prior to sample collection.

Rationale: The entire cohort is described as having Acute HIV Infection, which implies they are ART-naive at the time of diagnosis and sampling. There is no subgroup described as being ART-experienced.

Answer: No
"""

"""
Question: 4104

Evidence: A total of 47 patients with AHI were found. The study focuses on Acute HIV Infection (AHI).

Rationale: The paper defines its cohort as patients with Acute HIV Infection. By the nature of this early infection stage, all 47 individuals are inferred to be ART-naive at the time of sample collection.

Answer: 47
"""

"""
Question: 4105

Evidence: The paper is a retrospective study of Acute HIV Infection. It does not provide detailed ART history for the individuals.

Rationale: The paper focuses on the acute stage of infection, where patients are unlikely to have started ART. It does not include a table or section detailing the ART history of the participants, as this is not relevant to the study's focus on diagnosis and characteristics of AHI.

Answer: No
"""

"""
Question: 4201

Evidence: The drug resistance mutation rate was relatively high (17.65%) and five different mutations were identified.

Rationale: The paper reports a drug resistance mutation rate of 17.65% in individuals with Acute HIV Infection. Resistance in individuals who are ART-naive (as AHI patients are) is considered transmitted drug resistance.

Answer: Yes
"""

"""
Question: 4202

Evidence: The drug resistance mutation rate was relatively high (17.65%) and five different mutations were identified.

Rationale: Pretreatment HIV Drug Resistance (PDR) includes both transmitted drug resistance and resistance in ART-naive individuals. The paper reports a resistance mutation rate in ART-naive individuals with AHI, which falls under the definition of PDR.

Answer: Yes
"""

"""
Question: 4301

Evidence: The paper focuses on characterizing Acute HIV Infection and does not describe any treatment administered to the patients as part of the study.

Rationale: The study is observational and diagnostic. It reports on the natural history and virological characteristics of AHI at the time of diagnosis, not on treatment regimens or outcomes. No specific drug classes received by individuals are mentioned.

Answer: NA
"""

"""
Question: 4302

Evidence: The paper focuses on characterizing Acute HIV Infection and does not describe any treatment administered to the patients.

Rationale: The study is observational and does not report on the treatment history of the individuals, including whether they received integrase inhibitors.

Answer: No
"""

"""
Question: 4303

Evidence: The paper focuses on characterizing Acute HIV Infection and does not describe any treatment administered to the patients.

Rationale: The study is observational and does not report on the treatment history of the individuals, including whether they received protease inhibitors.

Answer: No
"""

"""
Question: 4304

Evidence: The paper focuses on characterizing Acute HIV Infection and does not describe any treatment administered to the patients.

Rationale: As no ART is described for the individuals in this observational study, the question of whether they all received the same ART is not applicable.

Answer: NA
"""

"""
Question: 4305

Evidence: The paper focuses on characterizing Acute HIV Infection and does not describe any treatment administered to the patients.

Rationale: The study cohort consists of individuals with Acute HIV Infection who are, by definition, ART-naive at the time of diagnosis. Therefore, they would not have received any INSTIs (Integrase Strand Transfer Inhibitors).

Answer: Yes
"""

"""
Question: 4403

Evidence: The paper focuses on characterizing Acute HIV Infection and does not describe any treatment administered to the patients.

Rationale: The study is observational and diagnostic, not interventional. It does not provide information on the number of ART regimens received by individuals.

Answer: NA
"""

"""
Question: 4404

Evidence: The paper focuses on characterizing Acute HIV Infection and does not describe any treatment administered to the patients.

Rationale: The study is observational and diagnostic, not interventional. It does not provide information on the number of ART regimens received by individuals.

Answer: NA
"""

"""
Question: 4405

Evidence: The paper focuses on characterizing Acute HIV Infection and does not describe any treatment administered to the patients.

Rationale: The study is observational and diagnostic, not interventional. It does not provide information on the ART regimens received by individuals.

Answer: NA
"""

"""
Question: 4406

Evidence: The paper focuses on characterizing Acute HIV Infection and does not describe any treatment administered to the patients.

Rationale: The study is observational and diagnostic, not interventional. It does not provide information on the ART regimens received by individuals.

Answer: NA
"""

"""
Question: 4501

Evidence: The paper focuses on characterizing Acute HIV Infection and does not describe any treatment administered to the patients.

Rationale: The study is observational and does not report on specific drugs, such as dolutegravir, received by the individuals.

Answer: 0
"""

"""
Question: 4502

Evidence: The paper focuses on characterizing Acute HIV Infection and does not describe any treatment administered to the patients.

Rationale: The study is observational and does not report on specific drugs, such as darunavir, received by the individuals.

Answer: """
Question: 5101

Evidence: Primary drug resistance mutations occurred in six cases. The drug resistance mutation rate was relatively high (17.65%).

Rationale: The paper explicitly states that drug resistance mutations were found in six individuals. It also calculates the mutation rate as 6 out of 34 successfully sequenced strains, which is 17.65%.

Answer: 6
"""

"""
Question: 5102

Evidence: Four drug resistance mutations in RT region were all nonnucleoside reverse transcriptase inhibitors with one E138A, one V179D, and two V179Es.

Rationale: The paper only reports drug resistance mutations in the Protease (PR) and Reverse Transcriptase (RT) genes. No mutations related to Integrase Strand Transfer Inhibitors (INSTIs) are mentioned, as the integrase gene was not sequenced.

Answer: 0
"""

"""
Question: 5103

Evidence: Four drug resistance mutations in RT region were all nonnucleoside reverse transcriptase inhibitors with one E138A, one V179D, and two V179Es.

Rationale: The paper lists the specific RT mutations found (E138A, V179D, V179E). None of these are known to be associated with resistance to Tenofovir Disoproxil Fumarate (TDF), which is a Nucleoside Reverse Transcriptase Inhibitor (NRTI). The mutations reported are for NNRTIs.

Answer: 0
"""

"""
Question: 5104

Evidence: The paper only reports drug resistance mutations in the Protease (PR) and Reverse Transcriptase (RT) genes.

Rationale: The methods describe sequencing the PR and partial RT regions of the pol gene. The integrase gene was not sequenced, and therefore no INSTI-resistance mutations could be reported.

Answer: NA
"""

"""
Question: 6101

Evidence: The paper reports genotypic drug resistance testing using sequencing and the Stanford database. It does not describe any phenotypic susceptibility tests.

Rationale: A thorough review of the methods and results finds no mention of phenotypic susceptibility testing, which involves growing virus in the presence of drugs.

Answer: No
"""

"""
Question: 6102

Evidence: The paper reports genotypic drug resistance testing. It does not describe any phenotypic susceptibility tests.

Rationale: Phenotypic susceptibility tests report IC (Inhibitory Concentration) values like IC50 or IC90. Since no phenotypic testing was performed, such values are not reported.

Answer: No
"""

"""
Question: 6103

Evidence: The paper reports genotypic drug resistance testing. It does not describe any phenotypic susceptibility tests.

Rationale: IC50 fold-change values are a metric from phenotypic susceptibility assays. Since no phenotypic testing was performed, these values are not reported.

Answer: No
"""

"""
Question: 6104

Evidence: The paper reports genotypic drug resistance testing. It does not describe any phenotypic susceptibility tests.

Rationale: The methods section only describes genotypic resistance testing via sequencing. No phenotypic susceptibility assay is mentioned.

Answer: NA
"""

"""
Question: 6105

Evidence: The paper reports clinical, virological, and molecular epidemiological characteristics. It does not mention experiments measuring viral replication capacity.

Rationale: Replication capacity refers to the inherent fitness of a virus, often measured in comparative growth assays. The paper does not describe any such experiments.

Answer: No
"""

"""
Question: 6106

Evidence: The paper reports genotypic drug resistance testing. It does not describe any phenotypic susceptibility tests.

Rationale: Since no phenotypic susceptibility testing was performed, no drugs were tested using this method.

Answer: NA
"""

"""
Question: 7101

Evidence: The paper describes sequencing viruses directly from patient plasma samples. All isolates were obtained from clinical specimens.

Rationale: Site-directed mutants are engineered in the laboratory to introduce specific mutations. The paper only reports on naturally occurring viruses from patients with Acute HIV Infection.

Answer: No
"""

"""
Question: 7102

Evidence: The paper content describes a clinical and molecular epidemiological study of patients with Acute HIV Infection. No mention is made of in vitro passage experiments.

Rationale: In vitro passage experiments involve serially passaging a virus in cell culture to study evolution. The paper's methodology is based on direct analysis of patient samples without such culture steps.

Answer: No
"""